Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma
JAMA Surgery · 01.11.2023 · 158 (11) · 1141
DOI: 10.1001/jamasurg.2023.4395 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Surgery, erschienen am 01.11.2023. Verfasst von Hoi Yan Ng und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, School of Clinical Medicine, The University of Hong Kong, Hong Kong (Special Administrative Region), People's Republ…. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Circulating Tumor DNA, Esophageal Neoplasms, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Esophageal squamous cell carcinoma (ESCC) is a deadly disease with frequent recurrence. There are unmet needs for prognostic biomarkers for dynamically monitoring disease progression and detecting minimal residual disease.
Objective
To examine whether circulating tumor DNA is clinically useful as a prognostic biomarker for ESCC recurrence and patient survival. Design, Setting, and Participants This single-center, population-based cohort study consecutively enrolled 147 patients receiving curative (n = 74) or palliative (n = 73) treatment at the surgery and clinical oncology departments of Queen Mary Hospital in Hong Kong from August 1, 2016, to September 31, 2021. Patients were followed up for 2 years. Plasma samples were collected at different longitudinal time points for a prospective circulating tumor DNA (ctDNA) next-generation sequencing profiling study of 77 actionable genes.
Intervention
Patients were treated with up-front surgery, neoadjuvant chemoradiotherapy plus surgery with or without adjuvant therapy, or palliative chemotherapy (CT). Main Outcomes and Measures Detection of circulating tumor DNA (ctDNA), progression-free survival (PFS), and overall survival (OS).
Results
A total of 478 serial plasma samples from 147 patients with locoregional or metastatic ESCC were prospectively analyzed. Among the 74 patients in the curative group (median [range] age, 66 [46-85] years; 56 [76.0%] male), 44 (59.5%) relapsed and 36 (48.6%) died. For patients receiving curative surgical treatment, a high ctDNA level (hazard ratio [HR], 7.84; 95% CI, 1.87-32.97; P = .005) and ctDNA alterations (HR, 5.71; 95% CI, 1.81-17.97; P = .003) at 6 months postoperation were independently associated with poor OS. Among patients receiving neoadjuvant chemoradiotherapy, postneoadjuvant ctDNA alterations were associated with poor PFS (HR, 3.16; 95% CI, 1.17-8.52; P = .02). In the 73 patients in the palliative group (median [range] age, 63 [45-82] years; 63 [86.0%] male), 71 (97.3%) had disease relapse and 68 (93.2%) died. Detectable pre-CT NFE2L2 alterations were independently associated with PFS (HR, 2.99; 95% CI, 1.35-6.61; P = .007) and OS (HR, 28.39; 95% CI, 7.26-111.03; P = 1.52 × 10 −6 ), whereas high ctDNA levels (HR, 2.41; 95% CI, 1.18-4.95; P = .02) and alterations in pre–cycle III ctDNA (HR, 1.99; 95% CI, 1.03-3.85; P = .04) showed weaker associations with PFS. Alterations in pre-CT ctDNA were independently associated with OS (HR, 4.46; 95% CI, 1.86-10.69; P = 7.97 × 10 −4 ). Conclusions and Relevance The findings of this cohort study indicate that prognostic models incorporating ctDNA features are useful in ESCC. Both ctDNA level and NFE2L2 alterations pre-CT and before cycle III were found to be important prognostic factors in palliative groups, and ctDNA alterations after treatment and at 6 months after surgery may define high-risk groups for recurrence in the curative group. High-risk patients can benefit by a timely switch to the next therapeutic options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Oncology, School of Clinical Medicine, The University of Hong Kong, Hong Kong (Special Administrative Region), People's Republic of China.
- Division of Anatomical Pathology, Queen Mary Hospital, Hong Kong (Special Administrative Region), People's Republic of China.
- Department of Surgery, School of Clinical Medicine, The University of Hong Kong, Hong Kong (Special Administrative Region), People's Republic of China.
Zitieren
APA
Ng, H. Y., Ko, J. M. Y., Lam, K. O., Kwong, D. L. W., Lo, A. W. I., Wong, I. Y. H., Wong, C. L. Y., Chan, S. Y., Chan, K. K., Law, T. T., Dai, W., Fong, H. C. H., Choy, F. S. F., Lo, C. K., Chen, C., Law, S. Y. K., & Lung, M. L. (2023). Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma. JAMA Surgery, 158(11), 1141. https://doi.org/10.1001/jamasurg.2023.4395
Vancouver
Ng HY, Ko JMY, Lam KO, Kwong DLW, Lo AWI, Wong IYH, et al. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma. JAMA Surgery. 2023;158(11):1141. doi:10.1001/jamasurg.2023.4395
BibTeX
@article{Ng2023,
author = {Ng, Hoi Yan and Ko, Josephine Mun Yee and Lam, Ka On and Kwong, Dora Lai Wan and Lo, Anthony Wing Ip and Wong, Ian Yu Hong and Wong, Claudia Lai Yin and Chan, Siu Yin and Chan, Kwan Kit and Law, Tsz Ting and Dai, Wei and Fong, Henry Chun Hung and Choy, Faith Sin Fai and Lo, Chun Kit and Chen, Cancan and Law, Simon Ying Kit and Lung, Maria Li},
title = {Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma},
journal = {JAMA Surgery},
year = {2023},
volume = {158},
number = {11},
pages = {1141},
doi = {10.1001/jamasurg.2023.4395}
}
EUVIMED